• RAPT

RAPT Therapeutics stock rises following licensing deal with Jemincare

RAPT Therapeutics' shares rose after a licensing deal with Shanghai Jemincare for RPT904, an anti-IgE antibody, and plans for upcoming clinical trials and a private placement.